论文部分内容阅读
目的验证ＴＨＰ－ＡＤＭ联合用药治疗恶性肿瘤的疗效与安全性。方法采用含ＴＨＰ－ＡＤＭ方案治疗２１种肿瘤２１９例，其中１４例肿瘤得到完全缓解或部分缓解。结果在可评价疗效的１６８例中，达ＣＲ４５例，ＰＲ５５例，有效率为５９．５％。恶性淋巴瘤有效率为８７．０％，急性白血病８５．７％，头颈部癌６３．６％，乳腺癌５８．３％，肺癌５４．８％，泌尿生殖系癌３３．３％，消化系癌３１．２％。２１９例的毒性反应，主要为骨髓抑制、消化道反应与脱发，但Ⅰ～Ⅱ度居多。心电图异常２．７％，血清转氨酶升高２３．６％。结论临床验证表明，ＴＨＰ是一抗癌活性强、广谱、毒性较低、安全性较好的蒽环类抗癌药物。
Objective To verify the efficacy and safety of THP-ADM in the treatment of malignant tumors. Methods Twenty-one cases of 21 tumors were treated with the THP-ADM regimen, of which 14 cases had complete or partial remission. Results Of the 168 cases that could be evaluated for efficacy, 45 were CR and 55 were PR, and the effective rate was 59.5%. The effective rate of malignant lymphoma is 87.0%, acute leukemia is 85.7%, head and neck cancer is 63.6%, breast cancer is 58.3%, lung cancer is 54.8%, urogenital cancer is 33.3%, digestion Department of cancer 31.2%. The toxicities of 219 cases were mainly myelosuppression, digestive tract reaction and hair loss, but the I-II degree was predominant. The abnormal electrocardiogram was 2.7%, and serum transaminases increased by 23.6%. Conclusion Clinical validation showed that THP is an anthracycline anticancer drug with strong anticancer activity, broad spectrum, low toxicity, and good safety.